Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia

About the study

MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease.

The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).

Study point of contact

Jude Jonassaint, RN
412-692-2086
jonassaintjc@upmc.edu
Mikhil N Bamne, PhD
(412) 648-6920
bamnemn2@upmc.edu

Locations

5 United States sites

Age

> 18 Years

Phase

Not Applicable

Study type

Interventional

Gender

All

Interventions

Dietary Supplement

participation requirements

Subjects

African American
Patients with sickle cell anemia
18 years old or older

Control

African American healthy controls
18 years of age or older

participation restrictions

Pregnancy,
Known hypertension,
Hemodialysis and active obstructive sleep apnea requiring treatment.
Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.

Locations

  • Pittsburgh, Pennsylvania, United States, Magee Women's Hospital, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, UPMC Montefiore, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, UPMC Presbyterian, 15213 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, Children's Hospital of Pittsburgh, 15224 [Recruiting]
  • Pittsburgh, Pennsylvania, United States, Hillman Cancer Center, 15232 [Recruiting]
Last updated 2022-01-18